Literature DB >> 30017539

Isolated para-aortic lymph node metastasis in FIGO stage IA2-IB2 carcinoma of the cervix: Revisiting the role of surgical assessment.

Marcela G Del Carmen1, Rene Pareja2, Alexander Melamed3, Juliana Rodriguez2, Anna Greer3, Rachel M Clark3, Laurel W Rice4.   

Abstract

OBJECTIVES: To investigate the utility of para-aortic lymph node dissection among women undergoing radical hysterectomy and pelvic lymph adenectomy for FIGO Stage IA2-IB2 cervical cancer using the National Cancer Database (NCDB).
METHODS: We identified patients with stage IA2-IB2 squamous cell, adenosquamous, or adenocarcinoma of the cervix diagnosed 2011-2014 in the NCDB. The primary outcome was the negative predictive value of histologically assessed pelvic lymph node status for para-aortic lymph node status among women undergoing pelvic and para-aortic lymph node dissection. We calculated probability of para-aortic lymph node metastasis conditional on pelvic lymph node status. Finally, we compared overall survival between patients undergoing para-aortic lymph node dissection and those in whom this procedure was omitted.
RESULTS: A total of 3212 patients met study inclusion criteria, of whom 994 (30.9%) underwent para-aortic lymph node dissection. In this group, the risk of isolated para-aortic metastasis was 0.11%. The negative predictive value of surgically assessed pelvic lymph nodes to predict para-aortic lymph node status was 99.9% (95% CI 99.9-99.9). Among 93 patients with pelvic lymph node metastasis, 18 (19.4%) had concurrent para-aortic lymph node metastasis. There was no difference in overall survival between women undergoing pelvic and para-aortic lymph node dissection compared with those undergoing pelvic lymphadenectomy only (p = 0.69).
CONCLUSIONS: In patients undergoing radical hysterectomy and pelvic lymphadenectomy for stage IA2-IB2 cervical cancer, para-aortic lymph node dissection is not warranted based on the low risk of isolated metastatic disease, and lack of survival benefit associated with the procedure.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cervical cancer; Lymph nodes; Metastases

Mesh:

Year:  2018        PMID: 30017539     DOI: 10.1016/j.ygyno.2018.07.010

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  3 in total

Review 1.  [The 2019 FIGO classification for cervical carcinoma-what's new?]

Authors:  L-C Horn; C E Brambs; S Opitz; U A Ulrich; A K Höhn
Journal:  Pathologe       Date:  2019-11       Impact factor: 1.011

2.  Knockdown of BRCC3 exerts an anti‑tumor effect on cervical cancer in vitro.

Authors:  Feifang Zhang; Qun Zhou
Journal:  Mol Med Rep       Date:  2018-09-26       Impact factor: 2.952

3.  Data from small cell neuroendocrine carcinoma of the cervix: FIGO 2018 staging is more accurate than FIGO 2009.

Authors:  Yunqiang Zhang; Jingxin Ding; Keqin Hua
Journal:  J Int Med Res       Date:  2022-01       Impact factor: 1.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.